204 related articles for article (PubMed ID: 8060667)
21. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
22. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.
Wagner R; Deml L; Schirmbeck R; Niedrig M; Reimann J; Wolf H
Virology; 1996 Jun; 220(1):128-40. PubMed ID: 8659105
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
24. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.
Morrow WJ; Williams WM; Whalley AS; Ryskamp T; Newman R; Kang CY; Chamat S; Köhler H; Kieber-Emmons T
Immunology; 1992 Apr; 75(4):557-64. PubMed ID: 1592430
[TBL] [Abstract][Full Text] [Related]
25. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
[No Abstract] [Full Text] [Related]
26. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles.
Harris SJ; Gearing AJ; Layton GT; Adams SE; Kingsman AJ
Immunology; 1992 Nov; 77(3):315-21. PubMed ID: 1362183
[TBL] [Abstract][Full Text] [Related]
27. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120.
di Marzo Veronese F; Willis AE; Boyer-Thompson C; Appella E; Perham RN
J Mol Biol; 1994 Oct; 243(2):167-72. PubMed ID: 7523682
[TBL] [Abstract][Full Text] [Related]
28. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
29. The mixotope: a combinatorial peptide library as a T cell and B cell immunogen.
Estaquier J; Gras-Masse H; Boutillon C; Ameisen JC; Capron A; Tartar A; Auriault C
Eur J Immunol; 1994 Nov; 24(11):2789-95. PubMed ID: 7957571
[TBL] [Abstract][Full Text] [Related]
30. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M
J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393
[TBL] [Abstract][Full Text] [Related]
31. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
[TBL] [Abstract][Full Text] [Related]
32. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
Wagner R; Böltz T; Deml L; Modrow S; Wolf H
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
[TBL] [Abstract][Full Text] [Related]
33. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
[No Abstract] [Full Text] [Related]
34. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
Boudet F; Keller H; Kieny MP; Thèze J
Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
36. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
[No Abstract] [Full Text] [Related]
37. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
Resnick DA; Smith AD; Zhang A; Geisler SC; Arnold E; Arnold GF
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S47-52. PubMed ID: 7865333
[TBL] [Abstract][Full Text] [Related]
38. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
Kumar S; Seth P
Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
[TBL] [Abstract][Full Text] [Related]
40. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]